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Objectives: Acinetobacter baumannii is a bacterium responsible for health care-
associated infections, and it frequently develops multiple drug resistance (MDR).
The prevalence of antibiotic-resistant A. baumannii in Iran has increased, and
this may cause significant clinical problems. Therefore, in order to elucidate the
development of antibiotic resistance, we performed a systematic review of the
literature published on antibiotic-resistant A. baumannii reported in Iran.
Methods: Thirty-six publications that met the criteria for inclusion were
reviewed from an initial 87 papers. Selected papers published between 2008 and
September 2014, were categorized on the basis of the sample collecting year
been between 2001 and 2013.
Results: Analysis of data revealed that, in general, there was an increase in
antimicrobial resistance. During the initial time point of these studies (2001
e2007) there was a high rate of resistance to all antibiotics, with the exception
of carbapenems, lipopeptides, and aminoglycosides that had a low resistance
rate in comparison with the others. Also, the resistance rate was increased in one
group of these three antimicrobial groups from 2010 to 2013. In particular, there
was an increase in resistance to carbapenems (imipenem and meropenem) from
2010e2011 and 2012e2013, whereas no significant change in the resistance rate
of the other two antimicrobial groups (lipopeptides and aminoglycosides) during
the study time was observed, although we did observe certain trends in amikacin
(aminoglycoside group antibiotic) between 2011e2012 and 2012e2013.
Conclusion: These findings indicate that antimicrobial resistance of A. bau-
mannii in Iran has increased, which may very well affect the antimicrobial
resistance of this organism worldwide. Based on these results, novel prevention
and treatment strategies against A. baumannii infections are warranted.
Furthermore, these data may assist in revising treatment guidelines and regional
policies in care units to slow the emergence of antimicrobial resistance.r@gmail.com (A. Bahador).
ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
0) which permits unrestricted non-commercial use, distribution, and reproduction in any
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Acinetobacter baumannii is a gram-negative, strictly
aerobic, nonfermenting coccobacillus belonging to the
Moraxellaceae family [1]. Species belonging to this
genus are opportunistic pathogens with increasing rele-
vance in both community-acquired and nosocomial in-
fections, particularly among patients in intensive care
units (ICUs) and high-dependency units (HDUs) [2e5].
These organisms have been implicated in various in-
fections, including ventilator-associated pneumonia,
endocarditis, meningitis, and infections of the skin, soft
tissues, urinary tract, and those originating from pros-
thetic devices [4,6]. A. baumannii has been isolated
from numerous sources such as soil, water, animals, and
humans, while its presence in health care institutions
and on environmental surfaces has been extremely
difficult to control [6].
Three decades ago, A. baumannii infections were
effectively treated with traditional antibiotics [7,8]. By
contrast, it currently exerts resistance to nearly all major
classes of antibiotics, including broad-spectrum peni-
cillins, cephalosporins, carbapenems, most amino-
glycosides, fluoroquinolones, chloramphenicol, and
tetracyclines. In the past decade, multidrug resistant
(MDR) clinical isolates have shown global distribution
[3]. Therefore, this pathogen has become a “red-alert”
for the following reasons: rapid emergence of resistance,
increased incidence, and the worldwide spread of MDR
isolates [7]. The rapid spread of MDR strains in noso-
comial infections that exhibit resistance to most or all
common antibiotics is a troubling evolution [3]. Thus, a
study of the antibiotic resistance patterns both in indi-
vidual hospitals and on countrywide levels may help to
clarify the mode of A. baumannii antibiotic resistance
spread and epidemiology worldwide [9]. The current
review was performed to elucidate the mode of antibi-
otic resistance of A. baumannii in Iran.2. Materials and methods
2.1. Database searches
Biomedical databases (Scopus, Medline, Web of
Science, EBSCO, IranMedex) were searched in order to
retrieve all related manuscripts published in English and
Persian. The search identified publications of epidemi-
ological studies in order to compile adequate informa-
tion on A. baumannii antimicrobial resistance in Iran.
The following key words were used: “Acinetobacter
baumannii and Iran”, “antimicrobial resistance and
Acinetobacter baumannii and Iran”, “antimicrobial
resistance and either gram negative bacilli and Iran or
Iran”, “nosocomial or hospital acquired and Iran” .
Study publications were obtained through PubMed,
MEDLINE, and IranMedex database searches. Also,
references cited within these articles were used to findadditional relevant articles. In this review, A. baumannii
susceptibility breakpoints based on Clinical Laboratory
Standards Institute (CLSI)-relevant antibiotics were
primarily those listed by the World Health Organization
Recommended Surveillance Standards.
2.2. Study settings
From the first 87 papers, we identified a total of 36
that were written in English and considered to be
eligible for inclusion in this review. The selected papers
were published between 2008 and September 2014. We
categorized studies on the basis of sample collection
year, between 2001 and 2013; some papers collect
samples during different years (Table 1). Two studies
were performed in three regions of Iran, including
central, north, and south. Twenty-two studies were
performed north of Iran, with 18 in Tehran (capital of
Iran). Two studies occurred in the south of Iran, three in
the west, and three in the east. Although the studies used
various methods, they were all approved by the CLSI
and the National Committee for Clinical Laboratory
Standards (NCCLS) and, therefore, suitable for trend
analysis.
2.3. Microbiological methods
Clinical specimens in studies were collected from
hospitalized patients with different disease and various
sampling. Twenty of the studies obtained data from
various clinical specimens, including blood, cerebro-
spinal fluid, urine, sputum, and respiratory tract samples.
Data from eight studies were obtained from patients
with burn wounds and seven from hospitalized patients
in ICUs. Antibiotic susceptibility testing methodologies
were declared in all studies, all of which were performed
according to the CLSI breakpoints. Twenty-six studies
used the Kirby-Bauer disk diffusion method, nine used
the E-test, and two used broth microdilution. To identify
resistance genes, 25 of the studies used one or more
polymerase chain reaction-based molecular methods.3. Results
3.1. Phenotypic resistance rates for different
antibiotics
The susceptibility data for 3049 A. baumannii iso-
lates are shown in Table 2. These data reflect the 12-year
period from 2001 to 2013 of sampling time in the studies
identified. The data demonstrate that, with the exception
of carbapenems, lipopeptides, and aminoglycosides,
there was a high rate of resistance to antimicrobial
groups during the initial time point of this study
(2001e2007). Also, the resistance rate was increased in
one group of these three antimicrobial groups from 2010
to 2013. In particular, there was an increase in resistance
to carbapenems (imipenem and meropenem) from
2010e2011 and 2012e2013, whereas no significant
Table 1. Characteristic of Acinetobacter baumannii antimicrobial resistance studies in Iran.
Year of publication (Refs)
Year of sample
collecting
No. of
studies
Total
samples
Location of Iran
(No. of studies)
2008 [10], 2010 [11], 2011 [12], 2014 [13] 2001e2007 4 383 Capital (4)
2011 [14], 2011 [15] 2007e2008 2 275 Capital (1), South (1)
2010 [16], 2010 [17], 2011 [14], 2011 [18],
2011 [12], 2012 [19], 2012 [20], 2013 [21]
2008e2009 8 680 Capital (1),North (3),
West (2),South (1), East (1)
2011 [22], 2012 [23], 2013 [24] 2009e2010 3 276 Capital (3)
2012 [25], 2012 [26], 2013 [27], 2013 [28],
2013 [29], 2013 [30], 2013 [31], 2013 [32],
2013 [33],
2013 [34], 2014 [35], 2014 [36], 2014 [37]
2010e2011 12 970 Capital (6),North (4),East (1),
West (1)
2013 [30], 2013 [32], 2013 [38],
2013 [39], 2014 [13], 2014 [40]
2011e2012 6 525 Capital (5), East (1)
2013 [41], 2013 [42], 2014 [43], 2014 [44] 2012eSep 2014 4 308 Capital (3), North (1)
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groups (lipopeptides and aminoglycosides) during the
study time was observed, although we did observe
certain trends in amikacin (aminoglycoside group anti-
biotic) between 2011e2012 and 2012e2013.
There are data regarding resistance to penicillins
from 2001 to 2011. There was a remarkable increase in
piperacillin resistance (from 63.9% in 2001e2007 to
93.4% in 2010e2011). The resistance rate to the b-
lactam/b-lactamase combination group was high early in
the study, with no substantial change to the study
endpoint. The highest level of antimicrobial resistance
throughout the study was noted among the cephems
group (>90%), including ceftazidime, cefepime, cefo-
taxime, and ceftriaxone. Resistance to carbapenems was
low at the study start point (51.1% imipenem, 64.3%
meropenem) and increased by the end of the study
(76.5% imipenem, 81.5% meropenem), thus demon-
strating the most drastic increase in resistance rate. A
low level of resistance at the starting point was also
observed for lipopeptides (polymyxin B and colistin),
with no significant trends as the study progressed. The
resistance rate to aminoglycosides was low, with the
exception of amikacin (from 58.4% in 2001e2007 to
95% in 2012e2013). At the beginning of the study,
there were no data for tetracyclines, whereas there was a
high level of resistance to this group at the study
endpoint. Resistance to fluoroquinolones was high dur-
ing the study period with no remarkable pattern change.
Finally, an increased resistance rate to folate pathway
inhibitors, including trimethoprim sulfamethoxazole,
was observed (from 76.6% in 2001e2007 to 99% in
2012eSeptember 2014). In summary, these data
demonstrate a high resistance rate to all antimicrobial
agents except lipopeptides.3.2. Genotypic resistance rate
Genotyping of a total of 1717 A. baumannii isolates
was performed in 17 studies. Table 3 shows themechanisms of resistance that were studied for the
different antibiotic classes from 2001 to 2013. The
genotyping methods in all studies were polymerase
chain reaction- and sequence-based. Among the 17
studies, 14, three, three, and one of them were focused
on b-lactams, tetracyclines, aminoglycosides, and
quinolones, respectively. These genotypic studies
demonstrated that isolates harboring resistance genes
have increased from 2001 to 2013, which is most
remarkable for carbapenem.
3.3. Distribution of multidrug resistance
By definition, MDR A. baumannii isolates are resis-
tant to three or more agents of different antibiotic
classes. In total, seven studies revealed the presence of
MDR isolates. Among these seven studies, this analyzed
584 A. baumannii isolates, MDR rates ranged from
32.7% to 93%. Chronologically, these rates can be
broken down as follows: 2001e2007 (1 study, 50%),
2008e2009 (1 study, 66%), 2009e2010 (1 study, 83%),
and 2010e2011 (4 studies, 32.7%, 74.9%, 93%, 94.4%,
respectively). In general, the prevalence of MDR
increased throughout the duration of the study.4. Discussion
A. baumannii infection has become a critical chal-
lenge to health care systems. To become an optimally
successful pathogen, an organism must develop anti-
microbial resistance. Although there is debate regarding
the definitions of “multidrug” and “pandrug” resistance
[45], an understanding has been reached in that resis-
tance to all common antimicrobial agents is currently a
common problem in health care institutions [46,47]. The
emergence of MDR isolates has become a serious
problem that has made it difficult to select an empirical
antimicrobial for the treatment of A. baumannii in-
fections. Therefore, monitoring the antibiotic resistance
Table 2. Phenotypic antibiotic resistance rates in Acinetobacter baumannii isolate from Iran.
Antibiotic
agents
Mean resistance rate (%) in different studies
2001e2007
n Z 383 (4 studies)
[10e13]
2007e2008
n Z 275(2 studies)
[14,15]
2008e2009
n Z 620(7 studies)
[12,14,17e21]
2009e2010
n Z 276(3 studies)
[22e24]
2010e2011
n Z 907(12 studies)
[25,26,29e37]
2011e2012
n Z 280(4 studies)
[13,38e40]
2012eSep 2014
n Z 308(4 studies)
[41,43]
PIP 69.9 88.2 93.75 98 93.4 d d
MZ d d d d 81.7 d d
TIC 100 d 100 d 94 d d
SAM 83.3 27.8 63.5 48.39 33.7 d 77.5
TZP 52.9 35.3 88.6 71.5 97.3 82.5 70
TIM 100 d 82.6 d 94 80 d
CAZ 93.5 90.7 92 93 92.6 d 97
FEP d 94.1 89 96.6 88.6 d 97
CTX 95 100 94 99 96.1 98 97
CRO 89.1 100 93.6 97.3 95.6 d 97.5
IPM 51.1 32 57.75 52.4 81.9 80.5 76.5
MEM 64.3 27.8 59.25 72 85.2 81.5 81.5
PB 8.8 d 16 3 13.5 3 9.5
CST d 1.3 19 12 9.3 d 16
GEN 76.85 81.9 83.75 40.6 82.9 63 78.5
TOB 63.2 39.2 d 28 60.9 56 70
AMK 58.4 79.4 82.7 69.5 75 89.5 95
NET 80.5 d d d 69.6 d d
TET d d d 34.78 83.82 51 56
DOX d d d d 25 d 42.9
MIN d d d d 25.6 d 34
CIP 83.9 67.6 83.75 92 85.2 97 72
LVX 83.3 d 81.75 d 81.25 d 99
GAT d d d d 43.3 d d
SXT 76.6 82.4 87.3 d 94.3 d 99
AMK Z amikacin; CAZ Z ceftazidime; CIP Z ciprofloxacin; CRO Z ceftriaxone; CST Z colistin; CTX Z cefotaxime; DOX Z doxycycline; FEP Z cefepime; GAT Z gatifloxacin; GEN Z gentamicin;
IPMZ imipenem; LVXZ levofloxacin; MEMZ meropenem; MINZ minocycline; MZZ mezlocilli; NETZ netilmicin; PBZ polymyxin B; PIPZ piperacillin; SAMZ ampicillin/sulbactam; SXTZ trimethoprim/
sulfamethoxazole; TET Z tetracycline; TIC Z ticarcillin; TIM Z ticarcillin/clavulanic acid; TOB Z tobramycin; TZP Z piperacillin/tazobactam.
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Table 3. Genotypic resistance rate in Acinetobacter baumannii isolate from Iran.
Antimicrobial
class Resistance mechanism Genes
Mean Resistance rate (%) in different studies
References
2001ee2007
n/N Z 2/208
2007e2008
n/N Z 0/0
2008e2009
n/N Z 3/360
2009e2010
n/N Z 2/226
2010e2011
n/N Z 7/602
2011e2012
n/N Z 1/31
2012eSep 2014
n/N Z 2/302
b-lactams b-lactamases PER-1 51 54.3 27.6 78.03 21,27,23,45
PER-2 0 21
VEB-1 10 39.5 21,45
TEM-1 47.2 13.1 27,23
SHV 5.6 23
ISAba1/ampC 46 63.1 27,20
ISAba 25/ampC 7.8 27
Carbapenemases OXA-23 -like 25, 55 24.58,84 30,67,77.9, 80 70.1 28,30,27,
23,20,22,
12,37,44
OXA-40 -like 17.1,47 35.8 28,27,44
OXA-58 -like 21.2 12
OXA-24 -like 15, 19.2 12,34
OXA-51 -like 96 94 14.4 28,22,10
IMP 19 3.48 18,45
VIM 9 17.44 18,45
Tetracyclines Efflux pump Tet A 11 36
Tet B 99,86.1 19.4 36,37,44
Aminoglycosides Enzymatic
degradation
aph(30)-IIb 61.8 29
aac(60)-Ib 60.5 16.4 29,44
aph(30)-Ia 46.1 19.4 29,44
ant(200)-Ia 14.5 56.7 29,44
ant(300)-Ia 10.5 29
aph(30)-Via 9.2, 95.5 29,44
aac(30)-Ia 5.3 32.8 29,44
aacC1 63.3 16
aadA1 41.7 16
aadB 3.3 16
aphA6 65 16
16s rDNA
methyltransferases
armA 9 44
Quinolones DNA
gyrase/topoisomerase
mutations
gyrA/parC 100 37
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84 J. Moradi, et alpatterns of this organism over time may provide useful
information regarding its treatment policy. This sys-
tematic review considered the distribution of antibiotic-
resistant A. baumannii in CLSI-approved studies pub-
lished in Iran between 2001 and September 2014.
According to the results, some level of resistance to
all antibiotic classes existed in the beginning of our
study. However, we revealed that the distribution of
antimicrobial resistance to all agents was high at the
endpoint, with the exception of the lipopeptides.
Currently, the antibiotics of choice for treatment of A.
baumannii infections include the aminoglycosides, flu-
oroquinolones, and carbapenems [48]. Thus, it is con-
cerning that our data demonstrate that A. baumannii
resistance to these agents increased over the time course
of this study, with a resistance rate in excess of 90% in
2013. As such, these antibiotics may not be appropriate
empirical therapy in many cases. For example, carba-
penems are one of the most clinically important classes
of antibiotics used against life-threatening A. baumannii
infections in Iran [10]. Our results showed that this
group of antibiotics had low-level resistance in
2001e2007 (51.1% imipenem, 64.3% meropenem),
which increased in 2012e2013 (76.5% imipenem,
81.5% meropenem). The data also showed that the most
drastic increase in resistance is associated with this
antibiotic class, possibly due to its frequency of use in
health care units. This is an alarming finding that
strongly suggests the possibility of treatment failures in
life-threatening A. baumannii infections due to
carbapenem-resistance strains.
As mentioned previously, our data show that resis-
tance to lipopeptides is lower compared with that of
other antimicrobial groups. One of the antibiotics of this
class is polymyxin B, which, despite previous concerns
regarding its toxicity, has been implemented in treat-
ment more frequently [49]. Another lipopeptide antibi-
otic is colistin, which has proven effective in the
treatment of wound, urinary tract, and bloodstream in-
fections [50], although its nephrotoxicity is a disad-
vantage to its use [51]. Although use of this antibiotic
class has limitations due to toxicity, they are often used
for the treatment of life-threatening infections.
In addition to an increase in antibiotic-resistant A.
baumannii strains from 2001 to 2013, the prevalence of
MDR strains also increased (from 50% in 2001e2007 to
74% in 2010e2011), with a mean prevalence of 71.2%.
Treatment of MDR strains is usually difficult, thus
creating critical challenges for health care consultants
[52,53]. The antibiotic choice for the treatment of MDR
A. baumannii infections is also limited and includes the
lipopeptides, [52,54] which the results of this study
suggest is the best class of antibiotics to use for MDR
because of the lower prevalence of resistance.
In summary, our results demonstrate the need for
effective surveillance of antimicrobial resistance in A.
baumannii in Iran and suggest that it is essential to useantibiotics with the most caution to prevent the emer-
gence of drug-resistant strains. Furthermore, these
findings indicate that the prevalence of antibiotic-
resistant A. baumannii is high in Iran, especially for
the antibiotics of choice. This is an emerging concern to
public health, particularly in the clinical management of
persons with life-threatening A. baumannii infections.
We strongly suggest the implementation of a country-
wide surveillance system. This would facilitate the
active monitoring of resistance frequency and distin-
guish antibiotic resistance trends and prevalence, all of
which would be effective tools in antibiotic treatment
programs.Conflicts of interest
None to declare.
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